


April 2002



Arizona State Board of Pharmacy

4425 W Olive Ave, Suite 140, Glendale, AZ 85302
Web site: pharmacy.state.az.us
e-mail: info@azsbp

Published to promote voluntary compliance of pharmacy and drug law.

New Board Members, Staff and Others

Governor Jane Dee Hull has appointed Linda K. McCoy to a five-year term as a pharmacist representing hospital pharmacy. Linda replaces Susan V. Ford. Governor Hull also has reappointed Eugene "Gene" Drake to a public member position, to serve a five-year term. Ms McCoy is a pharmacist at Good Samaritan Regional Medical Center – Phoenix and has served as a member of several Board of Pharmacy task forces, has been actively involved in both the Arizona Society of Health System Pharmacists, and the Arizona Pharmacy Association (APA) serving as APA president from 1996-1997. Mr Drake has been a public member of the Board of Pharmacy since 1997; his current term will expire in 2007. Mr Drake has served as Board of Pharmacy vice president and on the Board's Consumer Complaint review committee. Gene has been an active, productive Board member throughout his service.

Board members and staff extend a heartfelt **thank you** to Susan Ford for her dedicated service as a Board member and as president of the Board. Throughout her term, Susan served unselfishly and with distinction. Governor Hull was obligated to appoint a hospital pharmacist to the Board, thus precluding Susan from serving a second term at this time. Susan, you will be missed.

Antonio "Tony" Salcido, a pharmacy technician, has been hired as a non-pharmacy drug inspector. Tony will conduct inspections in firms holding a permit to sell over-the-counter drugs and will solicit compliance from non-permitted firms engaged in selling these items.

The unfilled position of "pharmacy compliance-officer" has been impacted by the hiring-freeze imposed on state agencies. We remain hopeful that we will receive permission to fill the position before the end of the fiscal year.

Congratulations to pharmacist Jane Lee of Peoria, Ariz, upon being accredited as a Certified Geriatric Pharmacist.

Law and Regulation Update

It is obvious that pharmacy law, including state and federal regulations, changes almost as rapidly as the pharmaceuticals themselves. For example, since the last Arizona

Board of Pharmacy *Newsletter*, new Arizona Intern Pharmacist Rules have been approved, new federal Drug Enforcement Administration (DEA) regulations on the sale of pseudoephedrine and phenylpropanolamine have been published, and the Food and Drug Administration is considering changes that address prescription drug compounding. One or more of these changes may impact your practice. The following information is only a summary intended to serve as a stimulus to research the literature for those that you feel are important. "Where would I look for such information?" Strange you should ask. You could start on the Arizona Board of Pharmacy Web site at www.pharmacy.state.az.us and click on the appropriate link to either state rules, state statutes or DEA regulations, or go directly to www.fda.gov and look for the appropriate button.

Significant changes to the Board's Intern Rules include: amending the definition of "supervision," adding the term "graduate-intern," increasing fees from \$10 to \$20 biennially and \$20 for the initial licensure. However, the \$10 wall certificate fee is deleted. The rule specifies standards for intern training sites and qualifications for preceptors, adds the term "graduate intern," and modifies the requirements of the intern's quarterly report, making the process less complex. There are changes in the ratio of interns per pharmacist, allowing more interns per preceptor in designated practice sites.

Another long-anticipated rule **currently being considered but not yet finalized** is the Collaborative Practice rule. This rule is required to be approved by both the Board of Medical Examiners and the Board of Osteopathic Examiners, thus the final rule making process is somewhat more prolonged. Once finalized, pharmacists will have the option of entering into agreements with medical practitioners to become involved in patient medication management. Several other states have adopted similar rules that have been operational for various lengths of time with many reports of improved patient medication outcomes. Watch future issues for further information.

Continued on page 4

Continued from page 1

Other rule making activity includes some minor format/grammar changes to two very brief sections: R4-23-501 and 502. See the Board's Web site for details.

The DEA recently has published new thresholds for retail and mail-order sales of pseudoephedrine and phenylpropranolamine products. The revised regulations state the thresholds for retail sales of pseudoephedrine and phenylpropranolamine in non-safe harbor packaging are reduced from 24 grams to nine grams for a single transaction and in package sizes of no more than three grams of either pseudoephedrine base or phenylpropranolamine base per package. The complexity and restrictions applying to the sale of these products make it evident that DEA is convinced that their uncontrolled sale poses a danger to public health and safety.

The following information is not actually a law/rule change, rather it is a product re-formulation. Endo Pharmaceuticals is introducing Percocet® 7.5/325 and 10/325 strengths. The reduced amount of acetaminophen per dosage unit will provide greater flexibility in managing patient pain relief while decreasing the daily intake of acetaminophen. Pharmacists are encouraged to make every effort to determine the accuracy of dispensing this product and to advise patients of the re-formulation.

Disciplinary/Reinstatement Actions

Board of Pharmacy

Jesse I. Kleinhesselink #10867 – license revoked January 10, 2002.

Jeffery P. Yannello #9192 – license suspended January 10, 2002, pending reinstatement of physician's assistant license.

Board of Medical Examiners

Barry L. Sack, MD #16110 – by consent order, Dr Sack agrees to not practice medicine and not prescribe medications until the medical board affirms that he may return to practice.

Board of Osteopathic Examiners

Eugene Hannibal Pardi, DO #2221 – on December 14, 2001 license was suspended for six months; previous Board Order amended, probation continues, shall not prescribe controlled substances for duration of probation (December 14, 2006).

Lillian Puma, DO #2836 – may not prescribe CII controlled substances while on probation.

Philo Rogers, DO #2809 – previous Board Order is amended, license placed on Probation for five years as of December 8, 2001, may not prescribe CII controlled substances while on probation.

Notice

Before making a prescription dispensing decision pursuant to information reported in this issue, you are advised to verify the current condition of a license with the appropriate licensing agency.


Pharmacists Assisting Pharmacists of Arizona (PAPA)

If you or a colleague is a candidate for assistance with an addiction or a substance abuse problem, contact Lisa Yates, Program Administrator of PAPA at 480/838-3668. The life you save may be your own.

Page 4 –April 2002

The *Arizona State Board of Pharmacy News* is published by the Arizona State Board of Pharmacy and the National Association of Boards of Pharmacy Foundation, Inc, to promote voluntary compliance of pharmacy and drug law. The opinions and views expressed in this publication do not necessarily reflect the official views, opinions, or policies of the Foundation or the Board unless expressly so stated.

Llyn A. Lloyd, RPh - State News Editor
Carmen A. Catizone, MS, RPh - National News Editor & Executive Editor
Courtney M. Karzen - Editorial Manager



ARIZONA STATE BOARD OF PHARMACY
National Association of Boards of Pharmacy Foundation, Inc
700 Busse Highway
Park Ridge, Illinois 60068